Mounjaro®
Starting from £179.99/mo
Start journey Learn morePiles (haemorrhoids) are not listed as a known side effect of Mounjaro in the licensed UK prescribing information, and there is no established direct link between tirzepatide and haemorrhoid development. That said, if you are starting treatment or considering it, the decision about how to manage any existing piles alongside Mounjaro is worth thinking through carefully — because some of the medicine's known effects on your digestive system can interact with a pre-existing tendency to haemorrhoids. Mounjaro is a prescription-only medicine; a prescriber assesses whether it is suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide slows gastric emptying and alters the pace at which food and fluid move through the digestive tract. For most people this manifests as nausea, especially in the first few weeks at a new dose, and changes to bowel habit, sometimes loose stools, sometimes constipation. The full Mounjaro overview covers the mechanism in more detail, but the key point here is that haemorrhoids are sensitive to exactly these two variables: stool consistency and straining frequency.
Hard, infrequent stools cause straining. Repeated loose stools cause irritation and mucosal inflammation. Both can provoke a flare in someone who already has internal or external haemorrhoids, even if the medicine itself is not directly causing the piles. The NHS patient information for tirzepatide lists constipation and diarrhoea among the common side effects and recommends contacting a doctor if they become severe or persistent, advice that is especially pertinent if you have an existing bowel condition.
Staying well hydrated matters on Mounjaro. The nausea phase sometimes puts people off fluids. A glass of water kept by the fridge alongside your pen can be a helpful reminder, small, practical, but it adds up when bowel regularity is already something you are managing.
The honest answer is: there is no evidence in the SURMOUNT clinical trial programme or the current UK SmPC that tirzepatide causes piles de novo. Haemorrhoids are extremely common (around one in two adults experiences them at some point) so any population on a medicine for several months will include people who develop or notice piles regardless of the treatment. Correlation is not causation here.
Where the connection becomes more plausible is in the context of pre-existing haemorrhoids. If your bowels tend toward constipation at baseline, the GI profile of tirzepatide (particularly during dose escalations) could tip you into a flare. Some people on Mounjaro also reduce their food intake significantly, which can lower dietary fibre intake if not managed carefully; lower fibre means harder stools. Our clinical team page has more on how prescribers at nume approach ongoing support during treatment. The question of whether piles on Mounjaro represent a direct pharmacological effect or a secondary consequence of gut changes is explored in more depth on the dedicated page on Mounjaro and haemorrhoid causation.
The short version: piles are not a listed reaction, but the conditions that provoke them can be created or worsened by tirzepatide's GI effects in some people.
First, tell your prescriber. Haemorrhoids are not a contraindication to tirzepatide, but active, symptomatic piles combined with significant GI side effects is a situation a clinician should know about. They may suggest timing dose increases to a period when your bowels are settled, or recommend dietary adjustments (adequate protein, adequate fibre, adequate water) to reduce the likelihood of bowel disruption.
Second, manage constipation proactively rather than reactively. If you know your tendency, speak to a pharmacist or GP before a flare begins. The Mounjaro patient information leaflet is the definitive reference for what to report and when. Over-the-counter topical treatments for haemorrhoids are generally compatible with tirzepatide, but check with a pharmacist for anything you are uncertain about.
Third, look at fibre and fluid. Reducing calories on Mounjaro is expected and beneficial, but processed, low-fibre choices are the path of least resistance when appetite collapses. A small amount of planning around meals keeps bowels functioning without needing to eat large volumes.
If you are wondering about the cost of treatment and whether the full package of clinical support is included, the Mounjaro cost page sets out what a private prescription service should include. At the gentle end of this topic, the weight-loss treatment overview puts Mounjaro in the broader context of what licensed options exist in the UK, including what clinicians consider the next best thing to Mounjaro for people who cannot use tirzepatide or are looking for alternatives. There is also growing curiosity about whether an oral form of tirzepatide could suit some patients, and our page on the Mounjaro pill explains where that research currently stands.
Piles are usually managed at home, but some presentations need prompt attention. See a GP or call 111 if you experience rectal bleeding that is significant, persistent, or accompanied by a change in bowel habit, unexplained weight loss beyond what you expect from treatment, or pain that is worsening rather than settling. Rectal bleeding should always be assessed rather than assumed to be haemorrhoidal, especially if it is new.
If you develop severe abdominal pain that radiates to your back (with or without vomiting) that is a separate concern: the MHRA's January 2026 Drug Safety Update highlighted acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, and that symptom warrants emergency assessment, not a wait-and-see approach. You can report any suspected side effect directly through the MHRA's Yellow Card scheme. For any other clinical question about Mounjaro and your specific health history, a consultation with a prescriber is the right first step, it is free with nume, and reviewed the same day by a real clinician.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.